a2408d
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1. Director/PDMR Shareholding
1 March 2022 15:30 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 28 February 2022
awards of AstraZeneca American Depositary Shares (ADSs) vested to
Dr Aradhana Sarin, Executive Director and Chief Financial Officer.
Each ADS represents one half of an Ordinary Share of $0.25 in the
Company.
In accordance with the Agreement and Plan of Merger, the awards
were granted under the AstraZeneca Global Restricted Stock Plan at
the time of closing of the acquisition of Alexion Pharmaceuticals,
Inc. (Alexion) by the Company. The awards replaced in-flight
Alexion awards originally granted to Dr Sarin between February 2018
and February 2021 under the Alexion 2017 Incentive Plan. The
replacement awards vested on completion of their respective holding
periods.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, 67,677 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the
awards was US$60.58, being the closing price on the last trading
day preceding the vesting.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Aradhana
Sarin
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Financial Officer
|
b)
|
Initial notification/Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
b)
|
Nature of the transaction
|
Acquisition
of AstraZeneca PLC American Depository Shares pursuant to a vesting
under the Global Restricted Stock Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
67,677
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
28
February 2022
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
01 March 2022
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|